Global Heart Failure Testing Market 2021 Focusing on Industry Growth and Emerging Trends briefingwire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from briefingwire.com Daily Mail and Mail on Sunday newspapers.
February 1, 2021 | 8:00 pm Font Size
AstraZeneca’s diabetes medicine approved for heart failure treatment
THE local Food and Drug Administration (FDA) has approved AstraZeneca’s medicine for diabetes as treatment for heart failure in adult patients. In a statement on Monday, AstraZeneca said its drug Dapagliflozin is “proven to significantly prevent cardiovascular death and death due to other causes in these heart failure patients.” The approval was based on the trial of Dapagliflozin and Prevention of Adverse-outcomes in Heart Failure Trial, which investigated a medicine for type 2 diabetes as treatment for heart failure in adult patients with reduced ejection fraction, or what is referred to locally as
(Photo by Paul ELLIS / AFP / MANILA BULLETIN)
With the FDA’s approval, Dapagliflozin is the first and only drug under the sodium glucose transport protein 2 inhibitor (SGLT2i) class approved to treat heart failure in adult patients with reduced ejection fraction (pumapalyang puso), AstraZeneca Philippines said in statement.
The multinational pharmaceutical company noted that the Dapagliflozin, a medicine for diabetes, is the only SGLT2i proven to significantly prevent cardiovascular death and death due to other causes among patients with heart failure.
AstraZeneca Philippines Country President Lotis Ramin expressed AstraZeneca’s commitment to uplift the standard of care of Filipino patients by providing them with innovative and accessible treatment.